MedTrace Logo

Gonadotropin Type in Ovarian Stimulation

NCT02437032 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2015-05-07

No results posted yet for this study

Summary

A key challenge facing reproductive biologists is the integration of the knowledge about oocyte-secreted factors into coherent physiological mechanisms of how oocytes govern folliculogenesis, cumulus cell function, and oocyte and embryo development. Although key oocyte-secreted factors have been identified, understanding their modes of action is complicated by multiple interactions between maternal and oocyte signaling molecules, as well as the constantly changing state of physical interactions between the oocyte and its companion somatic cells during folliculogenesis. Thus, the investigators study aimed to determine if there is any relationship between different gonadotropin preparations and oocyte-secreted factor secretion, the endocrine pattern in follicular fluid, and the apoptotic rate in cumulus cells during controlled ovarian stimulation.

Conditions

Interventions

DRUG

recombinant FSH

Controlled ovarian stimulation with 150-300 UI recombinant FSH

DRUG

Urinary FSH

Controlled ovarian stimulation with 150-300 UI urinary FSH

DRUG

hMG

Controlled ovarian stimulation with 150-300 UI hMG

Sponsors & Collaborators

  • IVI Madrid

    lead OTHER

Principal Investigators

  • Antonio Requena, PhD, MD · IVI Madrid

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2012-09-30
Completion
2012-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02437032 on ClinicalTrials.gov